Evidence map›Paper›PMID 35890406›Full record

ArticlePharmaceutics2022

The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b.

Yue-Zhi Lee, Hsing-Yu Hsu, Cheng-Wei Yang, Yi-Ling Lin, Sui-Yuan Chang, Ruey-Bing Yang, Jian-Jong Liang, Tai-Ling Chao, Chun-Che Liao, Han-Chieh Kao and 4 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Yue-Zhi Lee *Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan.
Hsing-Yu Hsu *Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan.
Cheng-Wei Yang *Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan.
Yi-Ling LinInstitute of Biomedical Sciences, Academia Sinica, Taipei 115021, Taiwan.ORCID 0000-0002-1838-6410
Sui-Yuan ChangInstitute of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei 10617, Taiwan.
Ruey-Bing YangInstitute of Biomedical Sciences, Academia Sinica, Taipei 115021, Taiwan.ORCID 0000-0003-3017-3714
Jian-Jong LiangInstitute of Biomedical Sciences, Academia Sinica, Taipei 115021, Taiwan.
Tai-Ling ChaoInstitute of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei 10617, Taiwan.
Chun-Che LiaoInstitute of Biomedical Sciences, Academia Sinica, Taipei 115021, Taiwan.
Han-Chieh KaoInstitute of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei 10617, Taiwan.
Jang-Yang ChangInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan.
Huey-Kang SytwuNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli 35053, Taiwan.
Chiung-Tong ChenInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan.ORCID 0000-0002-9432-6874
Shiow-Ju LeeInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan.ORCID 0000-0003-4012-0149
National Health Research Institutes · TWInstitute of Biomedical Sciences, Academia Sinica · TWNational Taiwan University · TW

Funding

Academia Sinica, Taiwan AS-CFII-108-102Ministry of Health and Welfare, Taiwan emergent grant of COVID-19Ministry of Science and Technology, Taiwan MOST 109-2327-B-002-009Ministry of Science and Technology, Taiwan MOST 109-2327-B-400-003Ministry of Science and Technology, Taiwan MOST 109-2811-B-400-518Ministry of Science and Technology, Taiwan MOST 109-3114-Y-001-001Ministry of Science and Technology, Taiwan MOST 110-2811-B-400-522National Health Research Institutes, Taiwan NHRI intramural fund
6 · The paper itself

Abstract

Ciclesonide is an inhaled corticosteroid used to treat asthma and has been repurposed as a treatment for mildly ill COVID-19 patients, but its precise mechanism of action is unclear. Herein, we report that ciclesonide blocks the coronavirus-induced production of the cytokines IL-6, IL-8, and MCP-1 by increasing IκBα protein levels and significantly decreasing p65 nuclear translocation. Furthermore, we found that the combination of ciclesonide and dbq33b, a potent tylophorine-based coronavirus inhibitor that affects coronavirus-induced NF-κB activation a little, additively and synergistically decreased coronavirus-induced IL-6, IL-8, and MCP-1 cytokine levels, and synergistically inhibited the replication of both HCoV-OC43 and SARS-CoV-2. Collectively, the combination of ciclesonide and dbq33b merits consideration as a treatment for COVID-19 patients who may otherwise be overwhelmed by high viral loads and an NF-κB-mediated cytokine storm.

Indexed as

ciclesonideCOVID-19cytokineIL-6IL-8MCP-1MCP-3OC43SARS-CoV-2tylophorine

Identifiers

PMID35890406
PMCPMC9325102
OpenAlexW4286433603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.